Childhood interstitial lung diseases (ILDs) are a diverse class of disorders affecting the alveolar gas exchange region that lack specific treatments and are usually fatal. Here, we integrate recent insights into alveolar cell biology with histopathology from well characterized mutations of surfactant-associated genes. We take a reductionist approach by parsing discrete histological features and correlating each to perturbation of a particular function of the alveolar epithelial type II (AT2) cell, the central driver of disease, to generate a working model for the cellular mechanisms of disease pathogenesis.
INTRODUCTION
The term childhood interstitial lung disease (ILD) is applied to respiratory disorders with defects in gas exchange resulting from diffuse abnormalities of the gas exchange (alveolar) region of the lungs that are not infectious in origin [1, 2] . Childhood ILDs are clinically and pathologically heterogeneous, although well described cohorts of patients and families in which full-term newborns presented with severe neonatal respiratory distress led to the discovery of causal mutations in several surfactantassociated genes, including ATP-binding cassette transporter A3 (ABCA3) [3] , surfactant protein B (SFTPB) [4] , and surfactant protein C (SFTPC) [5] . Surgical lung biopsy findings, chest imaging results, and clinical presentations often overlap, but no specific therapies exist and many cases lead to death in the neonatal period [1, 6] . There is a growing consensus that diffuse lung diseases presenting in infancy are distinct from those in adults, and therefore should no longer be classified using the adultunderlying cellular and molecular basis for overlapping and unique aspects of the observed alveolar pathology. Fortunately, modern tools and strategies enabling genome-scale molecular analysis [4, 8] and, in mice, in vivo cell fate mapping [5, 9] and gene manipulation [10] targeting specific alveolar cell types, have yielded important advances in lung biology. These include recent insights into how alveolar epithelial cells develop [11] and are maintained during aging and following injury [12] . Here, we integrate our updated understanding of alveolar cell biology with detailed histopathological descriptions of childhood ILDs to generate models for the cellular mechanisms of disease pathogenesis. We focus on ILDs presenting in infancy or early childhood with respiratory distress that are collectively classified as disorders of surfactant dysfunction [13 && ], for which the causative mutations are known and their molecular consequences well characterized. We hope our cellular framework positioning the alveolar epithelial type II (AT2) cell as the central driver of disease provides a scaffold upon which the specific molecular signals that mediate the alveolar pathology can be superimposed. Once a comprehensive understanding of the cellular and molecular basis for disease pathogenesis in childhood ILDs has been achieved, treatments may be devised that target the specific cells and molecular signals driving particular aspects of the alveolar pathology and dysfunction.
RECENT DISCOVERIES IN ALVEOLAR CELL BIOLOGY WITH SIGNIFICANT IMPLICATIONS FOR CHILDHOOD INTERSTITIAL LUNG DISEASES
A recent finding of importance for childhood ILDs is evidence indicating that AT1 and AT2 cells develop independently from a bipotent alveolar progenitor in the embryo, which contradicts the traditional view that AT1 cells derive exclusively by transdifferentiation of existing AT2 cells [14 && ]. The new model is based on several lines of evidence, including immunohistochemical analysis during alveolar cell differentiation, as well as indelible and heritable genetic marking of newly-formed AT2 cells, which were followed (fate-mapped) and found not to contribute to AT1 cells in development. In a follow-up study, transcriptional profiling of individual alveolar progenitor cells at progressive stages of maturation was performed using single cell RNA-sequencing, providing an incredibly rich (genomic) molecular characterization of the bipotent progenitor and the dynamic changes it undergoes as it differentiates into either an AT1 or AT2 cell [15 ] . AT2 cells were also fate-mapped in the adult lung, which showed that rare AT2 cells function as stem cells, demonstrating long-term self-renewal, multipotency, and activity throughout the lifespan [14 && ]. Execution of the progenitor function appears to involve two steps, the first being proliferation of a mature (surfactant-producing) AT2 cell, followed by direct transdifferentiation of one of the daughter AT2 cells into an AT1 cell. In some cases, for instance after selective AT2 cell ablation, the AT1 cell transdifferentiation step does not occur and both daughter cells retain an AT2 identity [16] . Interestingly, rare 'back-up' (non-surfactant, non-AT2) stem cells have recently been identified that are activated in severe influenza pneumonia with widespread alveolar cell death, but do not appear to function during aging [17, 18] . Whether these rare cells are present in embryonic or infant lungs is unknown.
Another mouse genetic experiment relevant for childhood ILDs also focused on the AT2 cell, although it was designed to investigate the pathogenesis of adult Idiopathic Pulmonary Fibrosis (IPF) [19] . This study was performed to test the model that failure to maintain an intact alveolar epithelium, for instance from depletion of AT2 stem cells, results in the myofibroblast activation and collagen deposition seen in IPF [20] . The investigators therefore attempted to specifically ablate AT2 cells in adult mice by genetically expressing the human diphtheria toxin receptor under control of the SFTPC promoter. Surprisingly, targeted AT2 cells were not killed when diphtheria toxin was administered, yet significant local fibrosis resulted after 2 weeks of daily toxin injections [21 & ]. These results indicate that intrinsic perturbation of mature AT2 cells (that does not result in cell death) alone is sufficient to trigger a local alveolar fibrotic response. The significance of this finding and of the other recent
KEY POINTS
Recent discoveries in lung developmental and alveolar cell biology provide novel insights into the cellular mechanisms of disease pathology in childhood ILDs.
Under or over-activity of distinct AT2 cell functions can account for specific aspects of childhood ILD pathology.
As genomic technologies become more widely applied, new mutations and candidate genes contributing to disease will continue to be discovered in patients with ILDs.
Mouse genetic technology provides an opportunity to interrogate the cellular and molecular mechanisms of putative causal mutations in hereditary surfactant associated disorders. discoveries in alveolar biology for childhood ILDs are discussed below.
FEATURES OF AND PROPOSED CELLULAR MECHANISMS FOR SEVERE CHILDHOOD INTERSTITIAL LUNG DISEASES PRESENTING IN INFANCY

ATP-binding cassette transporter A3 and surfactant protein B mutations resulting in absent protein
The ABCA3 gene is expressed in AT2 cells and encodes a membrane transporter protein that localizes to cytoplasmic organelles called lamellar bodies [22] that contain surfactant phospholipid, of which SP-B is an important component [23] . Both ABCA3 and SP-B are indispensable for functional surfactant, and lamellar bodies are not detectable in AT2 cells of patients with mutations in both copies of either gene that result in loss of protein expression [4, 24, 25] . Classical reports of ABCA3 deficiency described ultrastructural defects in the AT2 cell cytoplasm, specifically the presence of many dense inclusion bodies, along with the absence of normal lamellar bodies [3, 26] . Accumulations of alveolar macrophages and proteinaceous material in distal air sacs (originally referred to as an infantile Desquamative Interstitial Pneumonitis pattern), AT2 cell hyperplasia, and interstitial 'thickening' were also reported with ABCA3 deficiency. The pathologic findings significantly overlap with SFTPB mutations, which similarly result in alveolar proteinosis, AT2 cell hyperplasia, and interstitial 'widening.' Fibrosis in the absence of prominent inflammation has also been observed in several cases, but may not be a consistent feature because it was not described in every report [27] (Table 1) [1, 3, 4, 6, 25, 26, [28] [29] [30] [31] .
A canonical function of the AT2 cell is synthesizing, secreting, and recycling surfactant that coats the epithelial surface and minimizes surface tension to prevent alveolar collapse [23] . Pulmonary surfactant is primarily composed of phospholipids and its production initiates in maturing AT2 cells during late gestation [32] when the distinctive lamellar bodies can first be detected [33] . As expected, term infants with ABCA3 or SP-B deficiency present with respiratory failure, similar to infants born prematurely who have not yet begun producing surfactant. However, unlike premature babies, these infants cannot be rescued by exogenous surfactant replacement, suggesting additional consequences of these mutations. Since AT2 cells do not function as progenitors in development, AT1 cells presumably undergo normal differentiation directly from bipotent progenitors, implicating the AT2 cell as the sole driver of the observed pathologies. The histological findings of pneumocyte hyperplasia and fibrosis are not easily explained by deficiency of surfactant homeostasis (Fig. 1a) alone. We propose that the pneumocyte hyperplasia results from inappropriate activation of the proliferative step in the AT2 stem cell program (Fig. 1b) , although it is not clear that the hyperplasia adversely impacts gas exchange. Alternatively, AT2 cells could be appropriately proliferating in an attempt to repair acute alveolar epithelial injury, in which case the hyperplasia might reflect impairment of the second step of the AT2 stem cell program, transdifferentiation into an AT1 cell. For the fibrosis, we propose that a fibroblast-activating signal is produced by affected AT2 cells, perhaps the same one triggered in the AT2 cell-targeted injury experiment described above (Fig. 1c) . Why might an injury restricted to the AT2 cell result in fibroblast activation and collagen production? AT2 cells have been long known to maintain an intimate physical association with 
Alveolar proteinosis and lipid-laden ('foamy') macrophages fibroblasts [34] , and coordinated activity of these two cell types has been proposed to regulate normal alveolar development [35] and re-growth in rodents following experimental pneumonectomy [36] . It has also recently been demonstrated that AT2 cell proliferation in vitro is significantly enhanced by coculture with alveolar fibroblasts, providing further evidence of their functional interactions [16] . The identity of the putative fibroblast-activating signal is unknown, as is the nature of the AT2 cell-intrinsic dysfunction that triggers its production, but it does not appear to be a generalized response of AT2 cells to injury, as fibrosis is apparently not a feature of infantile ILD from SFTPC mutations.
Surfactant-associated protein C gene mutations resulting in misfolded and toxic protein
Lungs from infants presenting with respiratory failure from SFTPC mutations also share a characteristic set of histologic findings (1), termed Chronic Pneumonitis of Infancy [1, 28] . This stereotyped pattern was originally described by investigators who used histological features to distinguish and classify childhood diffuse lung diseases [28] . Although this study did not report the associated gene mutations, the constellation of pneumocyte hyperplasia, interstitial 'widening,' and alveolar wall thickening have since been regularly reported in infants with SFTPC mutations [1] . Unlike SP-B and ABCA3, SP-C is not critical for surfactant function and homozygous null mice that lack this protein do not exhibit respiratory failure at birth [37] (in contrast with mice homozygous for deletions of either the SFTPB [38] or the ABCA3 gene [39] [40] [41] ). Many disease-causing human mutations in the SFTPC gene do not abrogate protein expression, however, but rather map to a C-terminal domain of the pro-SP-C required for proper folding and transit through the secretory pathway [42] , resulting in cytoplasmic aggregation of misfolded SP-C that produces AT2 cell injury and death [42,43,44 & ]. The presence of only one mutant allele is sufficient to produce this toxicity, consistent with a functionally dominant effect and the observed autosomal dominant pattern of inheritance.
With SFTPC mutations, AT2 cells contain normal lamellar bodies and surfactant function is relatively intact, suggesting that loss of the canonical surfactant function of the AT2 cells is not responsible for the acute respiratory failure. A distinguishing feature of the disease pathophysiology with SFTPC mutations is that because SP-C is expressed by epithelial progenitors during lung development, bipotent (and earlier) embryonic progenitors, as well as newly-differentiating AT1 cells, could also experience toxicity and contribute to the alveolar pathology (Fig. 1d) . The presence of cholesterol clefts in the air sacs of infants with SFTPC mutations [29] suggests diffuse alveolar cell death, possibly because of widespread epithelial cell toxicity from the misfolded SP-C (Fig. 1d) . Whether the molecular signal producing pneumocyte hyperplasia is the same as in ABCA3 and SFTPB mutations is unknown, but the mechanism of AT2 cell-intrinsic dysfunction is presumably distinct given the differences in ultrastructural features of AT2 cells and absence of alveolar fibrosis in infants with SFTPC mutations. It is also possible that some or even all of the hyperplastic pneumocytes may result from bipotent progenitor toxicity that impairs cellular differentiation into AT1 cells, rather than increased proliferation (Fig. 1b) . Toxicity in epithelial progenitors at embryonic stages preceding alveolar cell differentiation could additionally dysregulate earlier steps in lung development [44 & ] including epithelialmesenchymal interactions, which may underlie the observed interstitial 'widening' and alveolar wall thickening.
PROPOSED MECHANISMS FOR CLINICOPATHOLOGICAL HETEROGENEITY OF INTERSTITIAL LUNG DISEASES PRESENTING BEYOND INFANCY
Interestingly, mutations in the SFTPC gene have also been found in adult ILDs [30, 31] and the clinical presentation of familial cases (where affected individuals harbor the identical mutation) can vary widely. The lack of mortality in infancy suggests that these mutations are intrinsically less severe or consequential (i.e., 'low impact') than the ones that are uniformly and rapidly fatal. For instance, the same mutations in SFTPC have been identified in individuals presenting with pulmonary disease associated with alveolar fibrosis both in adult life and in older children [30] . In such cases, including recently identified patients with ABCA3 mutations that do not abolish protein production [45] , we propose clinical disease results from interaction of a 'low-impact' mutation with patient-specific genetic modifiers and environmental exposures, as schematized in Fig. 2 . As they age, such individuals presumably experience the cumulative and independent toll of long-term deleterious effects of the mutation and environmental stressors, ultimately presenting with clinically apparent disease. We predict that as subtle lung disease is increasingly detected in adults and next-generation sequencing approaches are more widely applied to human cohorts, new mutations in surfactant-associated genes and their modifiers will be identified that contribute to alveolar pathology by dysregulating or depleting an essential AT2 cell function.
CONCLUSION
Genetic disorders of surfactant metabolism provide a valuable opportunity for dissecting the underlying pathogenesis of childhood ILDs, in particular how the bipotent progenitor and AT2 cell participate in mediating various features of the disease. Because absence or disruption of a single gene is sufficient to produce disease, these mutations are ideal for study using genetically engineered mice [44 & ], which afford a high degree of precision and enable robust experimental modeling not possible in patients. In parallel, increasingly powerful and affordable genomic technologies continue to emerge that can be harnessed to deeply profile distinct cell types and identify specific molecular pathways mediating the alveolar pathology in mouse or human lungs. We hope that our proposed framework for the cellular mechanisms of childhood ILD disease pathogenesis facilitates these efforts. 
